Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • AN AUDIENCE WITH

Electroceuticals jolt into the clinic, sparking autoimmune opportunities

As Galvani Bioelectronics advances its first ‘electroceutical’ candidate for a chronic disease into the clinic, company president Kristoffer Famm discusses the bioelectronic medicines R&D roadmap.
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed  Google Scholar

In 2016, GlaxoSmithKline and Alphabet life sciences company Verily staked a bold claim on the ‘electroceutical’ landscape. By launching Galvani Bioelectronics — a joint venture, backed by over US$700 million for 7 years — the partners set out to develop a new therapeutic modality that can harness the electrical signals that course through the body to treat various chronic diseases.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 21, 330-331 (2022)

doi: https://doi.org/10.1038/d41573-022-00072-8

Interviewed by Asher Mullard

Questions and answers have been edited for length and clarity.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links